• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Abbott launches glucose biosensor for athletes in Europe

Abbott launches glucose biosensor for athletes in Europe

September 17, 2020 By Sean Whooley

AbbottAbbott (NYSE:ABT) announced today that it is introducing the Libre Sense glucose sport biosensor for measuring athletes’ glucose.

The company touts the Libre Sense as the world’s first glucose sport biosensor, using Abbott’s FreeStyle Libre continuous glucose monitor (CGM) technology to become the first personal-use product that allows for use beyond diabetes, according to a news release.

Having received CE Mark approval in Europe, the Libre Sense is now available for consumers over-the-counter to give athletes at age 16 or older glucose monitoring capabilities through a mobile app while performing sports including cycling, running and swimming, offering a way to understand the efficacy of their nutrition choices in training and competition.

Athletes are to wear the small round biosensor on the back of their upper arm, and it will provide real-time glucose values during a wearability range of up to 14 days. That glucose data will wirelessly stream through Bluetooth every minute through compatible mobile apps and wrist readers.

The first non-exclusive collaboration for distribution of the technology is with Atlanta-based Supersapiens, which has partnered with teams at the Tour de France to put the system to use in training as part of an observational trial. The sensor will be available for purchase through the Supersapiens website.

Abbott said the Libre Sense will initially be made available commercially in Austria, France, Germany, Ireland, Italy, Luxembourg, Switzerland and the United Kingdom.

“FreeStyle Libre changed the way millions of people manage their diabetes to get and stay healthier, and now with Libre Sense we’re bringing that same proven technology to empower athletes to help them reach their athletic performance goals,” Abbott diabetes care senior VP Jared Watkin said in the release. “This is just the beginning – our breakthrough sensing technology has the potential to go beyond glucose and provide a lens into what’s happening in the human body that could provide meaningful insights into other conditions, treatments, and ultimately improve health.”

Filed Under: Business/Financial News, Diabetes, Featured, Health Technology, Patient Monitoring, Software / IT Tagged With: Abbott, CE Mark

More recent news

  • E2’s pulmonary embolism platform claims two FDA clearances
  • Resmed to launch AirTouch F40 full-face fabric CPAP mask in US
  • Paradromics taps Siemens Healthineers to develop scalable BCI imaging
  • THL Partners’ new hire to target medtech, life sci tool developers
  • Sequel Med Tech’s automated twiist pump scores FDA clearance in type 2 diabetes

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy